**Diversification of Noscapine Core Derivatives for Future Drugs**

Laxmidhar Rout\*; Elvire Picard, Jean-Claude Florent; Ludger Johannes; Emmanuel Bertounesque\*

Email: [routlaxmi@gmail.com](mailto:routlaxmi@gmail.com)\*, [Laxmidhar.Rout@curie.fr](mailto:Laxmidhar.Rout@curie.fr)\*,

\* U1143 INSERM, Institute Curie, Centre de Recherche, 26 rue d'Ulm, 75248 PARIS, France

The anti-tussive drug noscapine and analogs display anti-tumor activity by impairing tubulin polymerization without severe side effects. Noscapine causes mitotic arrest of tumor cells, induces apoptosis of tumor cells in vivo, and is in phase I/phase II clinical trials for multiple myeloma.[1] The coreunit of noscapine known as cotarnine, an oxidative degradation product of the drug, is a crystalline alkaloid which is available chiefly in salt form. Cotarnine hydrochloride is known to have hemostatic activity.[2] Additionally, cotarnine is the key component of tritoqualin (inhibostamin®) which is used as an anti-allergic drug,[3] and has been shown to have a preventive effect on liver injury in rats induced by treatment with CCl4.[4]  Hence, derivatization of cotarnine could pave the way to novel anticancer agents. Herein, we wish to report a practical and efficient method for synthesis of cotarnine derivatives. Other synthetic alkaloid generation exploiting this scaffold is underway.



References:

[1] (a) Karna, P. et. al, *Cell Death Differ.* **2011**, *18*, 632–644. (b) Aneja, R. et. al, *Eur. J. Cancer* **2010**, *46*, 1668–1678. (c) Kingston, D. G. I. *J. Nat. Prod.* **2009**, *72*, 507–515. (d) Ye, K. et. al, *Proc. Natl. Acad. Sci.* *USA* **1998**, *95*, 1601–1606. (e) Anderson, J. T. et.al, *J. Med. Chem.* **2005**, *48*, 7096–7098.; [2] (a) Kartsev, V. G. *Med.* *Chem. Res*, **2004**, *13*, 325–336.; [3] (a) *Drugs of the Future* **1986**, *11*, 951. (b) Sonneville, A. *Allerg. Immunol.* **1988**, *20*, 365–368.; [4] Hahn, F.; et.al, . *Arzeneim-Forsch,* **1970**, *20*, 1490–1495.